Insulet Co. (NASDAQ:PODD) Shares Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lifted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 7.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,661 shares of the medical instruments supplier’s stock after acquiring an additional 394 shares during the period. Janney Montgomery Scott LLC’s holdings in Insulet were worth $1,318,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Insulet during the 2nd quarter worth $32,000. UMB Bank n.a. lifted its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the last quarter. CVA Family Office LLC boosted its stake in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV grew its holdings in shares of Insulet by 159.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 156 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PODD shares. Canaccord Genuity Group boosted their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday. Citigroup raised their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Down 2.9 %

Shares of NASDAQ PODD opened at $261.16 on Friday. The stock has a market capitalization of $18.32 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The firm has a 50-day moving average price of $236.86 and a 200 day moving average price of $206.85. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.